![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ATP8B1 |
Gene summary for ATP8B1 |
![]() |
Gene information | Species | Human | Gene symbol | ATP8B1 | Gene ID | 5205 |
Gene name | ATPase phospholipid transporting 8B1 | |
Gene Alias | ATPIC | |
Cytomap | 18q21.31 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | O43520 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5205 | ATP8B1 | CA_HPV_2 | Human | Cervix | CC | 2.86e-02 | 1.89e-01 | 0.0391 |
5205 | ATP8B1 | CCI_1 | Human | Cervix | CC | 7.83e-10 | 9.43e-01 | 0.528 |
5205 | ATP8B1 | CCI_2 | Human | Cervix | CC | 1.03e-08 | 9.17e-01 | 0.5249 |
5205 | ATP8B1 | CCI_3 | Human | Cervix | CC | 1.29e-11 | 9.85e-01 | 0.516 |
5205 | ATP8B1 | sample3 | Human | Cervix | CC | 1.11e-05 | 1.74e-01 | 0.1387 |
5205 | ATP8B1 | H2 | Human | Cervix | HSIL_HPV | 1.30e-06 | 2.46e-01 | 0.0632 |
5205 | ATP8B1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.00e-50 | -8.64e-01 | 0.0155 |
5205 | ATP8B1 | HTA11_2951_2000001011 | Human | Colorectum | AD | 4.43e-11 | -9.18e-01 | 0.0216 |
5205 | ATP8B1 | HTA11_347_2000001011 | Human | Colorectum | AD | 4.33e-20 | 8.51e-01 | -0.1954 |
5205 | ATP8B1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 5.48e-10 | -5.58e-01 | -0.1207 |
5205 | ATP8B1 | HTA11_5216_2000001011 | Human | Colorectum | SER | 1.17e-04 | -4.10e-01 | -0.1462 |
5205 | ATP8B1 | HTA11_9341_2000001011 | Human | Colorectum | SER | 2.02e-09 | -9.56e-01 | -0.00410000000000005 |
5205 | ATP8B1 | HTA11_866_3004761011 | Human | Colorectum | AD | 7.08e-12 | -5.49e-01 | 0.096 |
5205 | ATP8B1 | HTA11_9408_2000001011 | Human | Colorectum | AD | 2.45e-05 | -6.36e-01 | 0.0451 |
5205 | ATP8B1 | HTA11_8622_2000001021 | Human | Colorectum | SER | 1.31e-03 | -4.20e-01 | 0.0528 |
5205 | ATP8B1 | HTA11_10711_2000001011 | Human | Colorectum | AD | 3.45e-11 | -6.21e-01 | 0.0338 |
5205 | ATP8B1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.05e-13 | -4.75e-01 | 0.0674 |
5205 | ATP8B1 | HTA11_11156_2000001011 | Human | Colorectum | AD | 4.24e-09 | -8.92e-01 | 0.0397 |
5205 | ATP8B1 | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.06e-12 | -6.79e-01 | 0.0588 |
5205 | ATP8B1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.47e-06 | -3.75e-01 | 0.294 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:01200325 | Stomach | CAG with IM | regulation of plasma membrane bounded cell projection assembly | 20/1050 | 186/18723 | 3.99e-03 | 3.46e-02 | 20 |
GO:00604914 | Stomach | CAG with IM | regulation of cell projection assembly | 20/1050 | 188/18723 | 4.50e-03 | 3.77e-02 | 20 |
GO:003252821 | Stomach | CSG | microvillus organization | 9/1034 | 24/18723 | 2.84e-06 | 1.23e-04 | 9 |
GO:003253021 | Stomach | CSG | regulation of microvillus organization | 6/1034 | 13/18723 | 3.43e-05 | 9.31e-04 | 6 |
GO:003003321 | Stomach | CSG | microvillus assembly | 6/1034 | 16/18723 | 1.39e-04 | 2.90e-03 | 6 |
GO:012003211 | Stomach | CSG | regulation of plasma membrane bounded cell projection assembly | 20/1034 | 186/18723 | 3.36e-03 | 3.04e-02 | 20 |
GO:006049111 | Stomach | CSG | regulation of cell projection assembly | 20/1034 | 188/18723 | 3.80e-03 | 3.36e-02 | 20 |
GO:003003331 | Stomach | CAG | microvillus assembly | 4/552 | 16/18723 | 1.03e-03 | 1.43e-02 | 4 |
GO:003252831 | Stomach | CAG | microvillus organization | 4/552 | 24/18723 | 4.97e-03 | 4.25e-02 | 4 |
GO:003253031 | Stomach | CAG | regulation of microvillus organization | 3/552 | 13/18723 | 5.85e-03 | 4.73e-02 | 3 |
Page: 1 2 3 4 5 6 7 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATP8B1 | SNV | Missense_Mutation | novel | c.794N>T | p.Cys265Phe | p.C265F | O43520 | protein_coding | deleterious(0) | possibly_damaging(0.822) | TCGA-A2-A25D-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
ATP8B1 | SNV | Missense_Mutation | c.2584N>T | p.Ala862Ser | p.A862S | O43520 | protein_coding | tolerated(0.12) | benign(0.178) | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
ATP8B1 | SNV | Missense_Mutation | novel | c.88N>A | p.Glu30Lys | p.E30K | O43520 | protein_coding | tolerated_low_confidence(0.17) | benign(0.339) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ATP8B1 | SNV | Missense_Mutation | novel | c.2224A>G | p.Ile742Val | p.I742V | O43520 | protein_coding | tolerated(0.06) | benign(0.298) | TCGA-BH-A1FU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
ATP8B1 | SNV | Missense_Mutation | novel | c.1663G>A | p.Glu555Lys | p.E555K | O43520 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
ATP8B1 | insertion | Frame_Shift_Ins | novel | c.225_226insTTCTCCTGCCTCAGCCTCC | p.Gln76PhefsTer19 | p.Q76Ffs*19 | O43520 | protein_coding | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
ATP8B1 | insertion | Nonsense_Mutation | novel | c.3405_3406insATCTGAATACAATCAATTTCCATTAGAAAGAAGGAGAGAGTAGAGG | p.Ala1136IlefsTer2 | p.A1136Ifs*2 | O43520 | protein_coding | TCGA-BH-A0HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | ||
ATP8B1 | SNV | Missense_Mutation | novel | c.3418N>A | p.Leu1140Met | p.L1140M | O43520 | protein_coding | tolerated(0.21) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ATP8B1 | SNV | Missense_Mutation | novel | c.3190N>C | p.Glu1064Gln | p.E1064Q | O43520 | protein_coding | tolerated(0.25) | probably_damaging(0.969) | TCGA-VS-A9UY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
ATP8B1 | SNV | Missense_Mutation | c.46N>G | p.Gln16Glu | p.Q16E | O43520 | protein_coding | tolerated_low_confidence(0.16) | benign(0.001) | TCGA-VS-A9UY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |